实用医学杂志2012，Vol.28Issue(20)：3444-3446,3.DOI:10.3969/j.issn.1006-5725.2012.20.050
吉非替尼与厄洛替尼二线治疗晚期非小细胞肺癌的对比研究
Comparison of the efficacy of gefitinib and erlotinib as a second line treatment for advanced non-small cell lung cancer
汪海岩 1张德芳1
作者信息
- 1. 221006 徐州医学院附属医院肿瘤内科
- 折叠
摘要
Abstract
Objective To compare the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and erlotinib alone as a second line treatment for patients with advanced non-small cell lung cancer (NSCLC) who were failed in the first-line chemotherapy. Methods Among the 83 patients who were failed in the first-line treatment for NSCLC, 41 received gefitinib (gefitinib group) and 42 received erlotinib (erlotinib) therapy. The efficacy, progression-free survival time (PFS), median survival time (MST), and toxicity of the two groups were compared. Results The median PFS and median OS were not significantly different between the two groups (P ＞ 0.05). The rate of adverse events in erlotinib group was higher than that in gefitinib group. The histological types of tumor were significantly different between the two groups (P ＜ 0.05), and the survival time in patients with squamous carcinoma in erlotinib group was longer than that in gefitinib group. Conclusion In the advanced NSCLC patients with standard first-line chemotherapy treatment failure, gefitinib and erlotinib had the similar overall efficacy.
关键词
癌,非小细胞肺/吉非替尼/厄洛替尼/化疗Key words
Non-small cell lung cancer, pulmonary/ Gefitinib/ Erlotinib/ Chemotherapy引用本文复制引用
汪海岩,张德芳..吉非替尼与厄洛替尼二线治疗晚期非小细胞肺癌的对比研究[J].实用医学杂志,2012,28(20):3444-3446,3.
